ReviewBlood research2023

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.

Jae Joon HanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.